Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Rhea-AI Summary

Journey Medical Corporation (NASDAQ:DERM) announced that its management team will ring the Nasdaq MarketSite closing bell on August 11, 2025, celebrating its 4-year anniversary as a public company and the commercial launch of Emrosi™, their new rosacea treatment.

CEO Claude Maraoui highlighted the company's consistent execution of its commercial strategy, led by their experienced management and specialized dermatology sales force. The company expects positive EBITDA later in 2025, citing strong initial revenue from Emrosi, improving margins, and a solid cash position.

Positive

• Initial Emrosi launch showing strong revenue performance
• Company expects to achieve positive EBITDA in 2025
• Reports improving profit margins
• Maintains strong cash position

Negative

• None.

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monday, August 11, 2025 at 4:00 p.m. ET. Journey Medical is celebrating its 4-year anniversary as a publicly traded company on the Nasdaq Stock Market and the commercial launch of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for the treatment of rosacea.

Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical, said, “The honor of ringing the Nasdaq Stock Market closing bell marks a proud and exciting milestone for our company. Since Journey Medical became a public company four years ago, we have consistently executed on our commercial strategy and made significant progress, which is led by our experienced management team and our unique, dermatology-focused sales force in the field. We are confident that the recent launch of Emrosi will continue to build momentum throughout the year. With strong initial revenue, improving margins, and a solid cash position, we believe we are on track to accelerate our path to profitability and achieve positive EBITDA later this year.”  

A live stream of the Nasdaq Closing Bell will be available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product, Emrosi™, and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

FAQ

When will Journey Medical (NASDAQ:DERM) ring the Nasdaq closing bell?

Journey Medical will ring the Nasdaq closing bell on August 11, 2025 at 4:00 p.m. ET at the Nasdaq MarketSite in Times Square.

What is Journey Medical's (DERM) new product Emrosi used for?

Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) is used for the treatment of rosacea.

When does Journey Medical (DERM) expect to achieve profitability?

Journey Medical expects to achieve positive EBITDA later in 2025, driven by strong initial revenue, improving margins, and solid cash position.

How long has Journey Medical (DERM) been a public company?

Journey Medical is celebrating its 4-year anniversary as a publicly traded company on the Nasdaq Stock Market.

Where can investors watch Journey Medical's Nasdaq bell ringing ceremony?

Investors can watch the ceremony via live stream at nasdaq.com/marketsite/bell-ringing-ceremony.